Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autonomous parvovirus vectors.

Ian H Maxwell1, Kristina L Terrell, Françoise Maxwell

  • 1Department of Dermatology and University of Colorado Cancer Center, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA. ian.maxwell@uchsc.edu

Methods (San Diego, Calif.)
|November 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.

Breast cancer research : BCR·2016
Same author

Thyroid hormone responsive protein Spot14 enhances catalysis of fatty acid synthase in lactating mammary epithelium.

Journal of lipid research·2014
Same author

RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway.

The Journal of investigative dermatology·2006
Same author

Parvovirus LuIII transducing vectors packaged by LuIII versus FPV capsid proteins: the VP1 N-terminal region is not a major determinant of human cell permissiveness.

The Journal of general virology·2004
Same author

Targeting diphtheria toxin A-chain transcription to activated endothelial cells using an E-selectin promoter.

Angiogenesis·2003
Same author

Storage of various cell lines at -70 degrees C or -80 degrees C in multi-well plates while attached to the substratum.

BioTechniques·2002

Autonomous parvoviruses (APVs) show promise as anticancer agents. APV-based vectors can deliver therapeutic genes, offering potential for cancer therapy and gene transfer applications.

Area of Science:

  • Virology
  • Oncology
  • Gene Therapy

Background:

  • Autonomous parvoviruses (APVs) are small, single-stranded DNA viruses.
  • APVs require proliferating cells for replication and can exhibit antitumor properties.
  • Rodent APVs like LuIII, MVM, and H1 can infect human cells, making them candidates for vector development.

Purpose of the Study:

  • To explore the potential of autonomous parvoviruses (APVs) and their derived vectors as anticancer agents.
  • To review the development and characteristics of APV-based vectors for gene transfer applications.

Main Methods:

  • Development of LuIII-based vectors with replaced coding sequences for transgene expression.
  • Engineering of MVM-based and H1-based vectors with substituted capsid sequences to retain NS1 protein for genome amplification.

Related Experiment Videos

  • Pseudotyping of LuIII vectors with heterologous capsid proteins to control tissue tropism and immune response.

    • Main Results:

    • APV vectors have a packaging capacity of approximately 4.8 kb.
    • LuIII vectors enable transient or persistent transgene expression.
    • MVM and H1 vectors express NS1 protein, potentially enhancing antitumor activity.
    • Pseudotyping and capsid modification strategies show success in targeting vectors.

    Conclusions:

    • APV vectors hold significant potential as gene transfer agents for experimental and therapeutic applications, particularly in cancer therapy.
    • Further advancements in production and purification are necessary for clinical translation.
    • The ability to control tissue tropism and immune responses enhances their therapeutic prospects.